enterprise THE DAVIS
WEDNESDAY, MARCH 9, 2022
Last two defendants in court for missing teens’ case
Donovan Nielsen became the first participant to receive the COVID-19 clinical trial vaccine candidate at UC Davis Health in 2020. Now, UCD is teaming up with Pfizer for two more studies. UC Davis Health/ Enterprise file photo
UCD, Pfizer team on booster trials By Caleb Hampton Enterprise staff writer UC Davis is partnering with Pfizer on two new clinical trials to test the pharmaceutical company’s COVID-19 booster vaccine in healthy adults. The trials will assess the efficacy of different strength booster doses and test possible side effects of a booster shot on the heart. When Pfizer’s mRNA COVID-19 vaccine was approved by the U.S. Food and Drug Administration in August 2021, the recommended course was a two-dose series of the vaccine. Since then, with the emergence of COVID-19 variants like Delta and Omicron, most health experts now recommend a three-dose course of the vaccine.
The FDA has authorized a 30-microgram booster dose of Pfizer’s COVID-19 vaccine — the same strength as the first two doses — for people 12 years or older. The booster should be taken at least five months after the initial two doses. “The development and approval of an effective COVID19 vaccine was an important milestone in our fight against COVID-19. But there is still a lot to understand about the virus and the immune response the vaccine creates,” said Timothy Albertson, professor and chair of the Department of Internal Medicine, who is leading both of the new clinical trials at UC Davis. “This includes studying the continued efficacy and possible side effects of the
COVID-19 vaccine.” UC Davis Health’s Sacramento clinic is recruiting double-vaccinated participants for both of the new clinical trials. To be eligible, participants should be healthy adults who have received the first two Pfizer doses, but not the booster, and have no history of severe allergic reaction to the vaccine or any of its components. The first study will assess the immune responses to different doses of the booster shot. Patients will be randomly assigned to receive either the standard 30-microgram dose of a reduced 10-microgram dose. They will attend five clinic visits over the course of one year. “As the pandemic continues, it is important to learn about
By Lauren Keene Enterprise staff writer
High levels of troponin are associated with heart injury. Participants in this study will receive a booster shot and a placebo injection four weeks apart, with some participants receiving the booster first and others
WOODLAND — Jury selection began Tuesday for the two remaining defendants accused of killing two local teens who went missing back in 2016. Chandale Shannon Jr. and Jesus Campos have pleaded not guilty to murder, kidnapping and weaponrelated charges in connection with the presumed deaths of Enrique Rios, 16, and 17-year-old Elijah Moore, whose bodies have never been found. Testimony is expected to begin later this month following the selection of 12 jurors and five alternates, who will hear the four-week trial on a week-on, week-off format. The trial is the second to be held in the case. The first, back in the fall of 2018, ended with David Ashley Froste’s conviction and sentencing to life in prison without the possibility of parole.
See TRIALS, Page A4
See COURT, Page A5
vaccine safety and the extent of the immune protection provided by a lower booster dose in adults who have received two prior doses,” said Angela Haczku, co-principal investigator on the trials and the associate dean for translational research at UC Davis Health. The second study will analyze levels of the heart protein troponin I in participants before and after they have received Pfizer’s booster shot.
Sisson updates COVID-19 case data Supervisors put DiSC on
ballot despite loose ends
By Anne Ternus-Bellamy Enterprise staff writer Yolo County’s COVID-19 case rate has declined by 95 percent since the height of the Omicron surge in January, the county’s health officer told the Board of Supervisors on Tuesday, and COVID-19 hospitalizations have plummeted by 86 percent. From an all-time high of 242 cases per 100,000 residents per day in January, the case rate hit 12.8 on Monday, said Dr. Aimee Sisson. Hospitalizations have declined from a high of 29 in January to just four on Monday. Now, for the first time since mid December, the
VOL. 124 NO. 29
INDEX
Classifieds ������ A5 Green Page ������ A6 Sports ��������������B1 Comics ������������B3 The Hub ������������B1 The Wary I �������� A2 Forum ��������������B4 Living ���������������� A3 Yolo Ages ��������� A6
By Anne Ternus-Bellamy Enterprise staff writer
Courtesy graphic
county no longer has high community transmission as defined by the Centers for Disease Control and Prevention but is instead in the orange “substantial transmission” category with 90 cases per 100,000 residents per week. Dropping to the yellow “moderate transmission” category will require fewer
WEATHER Thursday: Sunny and breezy. High 65. Low 38.
than 50 cases per 100,000 residents per week. Meanwhile, even as the BA.2 Omicron subvariant makes up a larger percentage of new local cases — nearly 30 percent, according to the UC Davis Genome Center — Sisson said she does not expect
See DATA, Page A5
The Yolo County Board of Supervisors voted unanimously on Tuesday to place the Davis Innovation and Sustainability Campus on the June ballot, but not without some trepidation. DiSC, which will be Measure H on the June 7 ballot, will require the annexation of county land by the city and issues related to both traffic and tax sharing between the entities remain unresolved. The city previously adopted a resolution calling for DiSC to go before
voters and requested that the special municipal election be consolidated with the statewide primary election in June. Normally the county would approve such a request with minimal discussion and on Tuesday the matter was on the board’s consent calendar for that purpose. But the two county supervisors who represent Davis — Jim Provenza and Don Saylor — wanted further discussion, with Provenza saying he wanted a status report “as to whether
HOW TO REACH US www.davisenterprise.com Main line: 530-756-0800 Circulation: 530-756-0826
http://facebook.com/ TheDavisEnterpriseNewspaper http://twitter.com/D_Enterprise
See DISC, Page A5
WED • FRI • $1